anti-MLL antibody product blog
Tags: Antibody; Monoclonal Antibody; MLL; anti-MLL antibody;
The MLL kmt2a (Catalog #MBS850510) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The MLL Antibody reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s MLL can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Immunohistochemistry (IHC), ELISA (EIA).WB: 1:500-1:2000
IHC: 1:200-1:1000
ELISA: 1:10000. Researchers should empirically determine the suitability of the MLL kmt2a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The MLL kmt2a product has the following accession number(s) (GI #308199413) (NCBI Accession #NP_001184033.1) (Uniprot Accession #Q03164). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the MLL Antibody with the following immunoassay(s):
Western Blot (WB) (Figure 1. Western blot analysis using MLL mouse mAb against truncated MLL recombinant protein (1) and truncated GFP-MLL(aa3714-3969) transfected Cos7 cell lysate (2).)
Immunohistochemistry (IHC) (Figure 2. Immunohistochemical analysis of paraffin-embedded human lung cancer (left) and esophagus cancer (right), showing nuclear weak staining with DAB staining using MLL mouse mAb.)
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila). Eukaryotic RNA polymerase II mediates the synthesis of mature and functional messenger RNA. This is a multistep process, called the transcription cycle, that includes five stages. preinitiation, promoter, clearance, elongation and termination. Elongation is thought to be a critical stage for the regulation of gene expression. ELL (11-19 lysine-rich leukemia protein, also designated MEN) functions as an RNA polymerase II elongation factor that increases the rateof transcription by suppressing transient pausing by RNA polymerase II. Also, ELL is thought to regulate cellular proliferation. ELL is abundantly expressed in peripheral blood leukocytes, skeletal muscle, placenta and testis, and has lower expression in spleen, thymus, heart, brain, lung, kidney, liver and ovary.The gene encoding human ELL, which maps to chromosome 19p13.1, is one of several genes which undergo translocation with the MLL gene on chromo-some 11q23 in acute myeloid leukemia. MLL (myeloid/lymphoid leukemia, also designated ALL-1 and HRX) is a 430 kDa protein that regulates embryonal and hematopoietic development.
Immunogen: Purified recombinant fragment of MLL (aa3751-3968) expressed in E. Coli. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing MLL are readily searchable from our website. Different antibodies against the same target such as MLL may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.